University of Texas System

Nordion (canada) Inc.

Psiloquest Inc.

Macrocyclics

Zoltan Kovacs

A Dean Sherry

Garry E Kiefer

Corinne Bensimon

Dhurjati S Mudigonda

Amit Kumar

Xiankai Sun

Cara L Ferreira

Matthew E Merritt

Mark Woods

In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.

Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

The present invention relates to the preparation of hyperpolarizedY. HyperpolarizedY may be used as nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI) agents for sensitive detection and imaging.

Hyperpolarized 89-yttrium and methods relating thereto

A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q, X, Y, Z, Z, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion ofY,In orLu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.

Bifunctional polyazamacrocyclic chelating agents

A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q, X, Y, Z, Z, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion ofY,Li orLu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.

The present invention is directed, in general, to a contrast agent comprising a tetraazacyclododecane ligand and comprising a macrocyclic ring and a paramagnetic metal ion coordinated to the tetraazacyclododecane ligand. Pendent arms R, R', R&#x2033; and R&#x2032;&#x2033; attached to a ring nitrogen. The pendent arms have the general formula: &#x2212;C&#x2032;HRRand for three or more of the pendant arms a chirality of the carbon atoms C&#x2032; are identical for each of three or more of the pendant arms. The Rgroup is larger than hydrogen and Ris selected from the group consisting of: an alcohol, amides, a carboxylate, phosphinates and a phosphonate. One or more substituents Ris a group larger than a methyl group and is located on one or more ring carbons.

Selection of coordination geometry to adjust water exchange rates of paramagnetic metal ion-based macrocyclic contrast agents

The present invention is directed, in general, to a method for making high yields of functionalized cyclic or acyclic tertiary amine-containing compounds, termed active esters, the functionalized compounds themselves, and diagnostic or therapeutic systems incorporating such compounds. Ester groups are attached to all but one of its Nitrogen atoms of the tertiary amine-containing compound. Therefore, an active agent, in the presence of coupling agent, attaches to the remaining amine via a carboxylate group attached to the amine, to produce high yields of the active ester. The active ester is then combined with a biomolecule, to produce high yields of a bioconjugated product. A metal ion may be chelated to the bioconjugated product to produce a chelating agent for use in either diagnostic or therapeutic applications.

Growing community of inventors

Lewisville, TX, United States of America

Zoltan Kovacs